Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 145

1.

VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.

Currier MA, Eshun FK, Sholl A, Chernoguz A, Crawford K, Divanovic S, Boon L, Goins WF, Frischer JS, Collins MH, Leddon JL, Baird WH, Haseley A, Streby KA, Wang PY, Hendrickson BW, Brekken RA, Kaur B, Hildeman D, Cripe TP.

Mol Ther. 2013 May;21(5):1014-23. doi: 10.1038/mt.2013.39. Epub 2013 Mar 12.

PMID:
23481323
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy.

Eshun FK, Currier MA, Gillespie RA, Fitzpatrick JL, Baird WH, Cripe TP.

Gene Ther. 2010 Jul;17(7):922-9. doi: 10.1038/gt.2010.82. Epub 2010 May 27.

PMID:
20508601
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody.

Patil SS, Gentschev I, Adelfinger M, Donat U, Hess M, Weibel S, Nolte I, Frentzen A, Szalay AA.

PLoS One. 2012;7(10):e47472. doi: 10.1371/journal.pone.0047472. Epub 2012 Oct 16.

PMID:
23091626
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.

Yoo JY, Pradarelli J, Haseley A, Wojton J, Kaka A, Bratasz A, Alvarez-Breckenridge CA, Yu JG, Powell K, Mazar AP, Teknos TN, Chiocca EA, Glorioso JC, Old M, Kaur B.

Clin Cancer Res. 2012 Sep 15;18(18):4931-41. Epub 2012 Jul 2.

PMID:
22753591
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Combination of the tumor angiogenesis inhibitor bevacizumab and intratumoral oncolytic herpes virus injections as a treatment strategy for human gastric cancers.

Deguchi T, Shikano T, Kasuya H, Nawa A, Fujiwara S, Takeda S, Gewen T, Sahin TT, Yamada S, Kanzaki A, Yamamura K, Fujii T, Sugimoto H, Nomoto S, Fukuda S, Nishikawa Y, Kodera Y, Nakao A.

Hepatogastroenterology. 2012 Sep;59(118):1844-50. doi: 10.5754/hge11566.

PMID:
22172413
[PubMed - indexed for MEDLINE]
6.

Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.

Workenhe ST, Simmons G, Pol JG, Lichty BD, Halford WP, Mossman KL.

Mol Ther. 2014 Jan;22(1):123-31. doi: 10.1038/mt.2013.238. Epub 2013 Oct 9.

PMID:
24343053
[PubMed - indexed for MEDLINE]
7.

VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth.

Yoo JY, Kim JH, Kwon YG, Kim EC, Kim NK, Choi HJ, Yun CO.

Mol Ther. 2007 Feb;15(2):295-302.

PMID:
17235307
[PubMed - indexed for MEDLINE]
8.

Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model.

Mahller YY, Vaikunth SS, Currier MA, Miller SJ, Ripberger MC, Hsu YH, Mehrian-Shai R, Collins MH, Crombleholme TM, Ratner N, Cripe TP.

Mol Ther. 2007 Feb;15(2):279-86.

PMID:
17235305
[PubMed - indexed for MEDLINE]
9.

Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models.

Passer BJ, Cheema T, Wu S, Wu CL, Rabkin SD, Martuza RL.

Cancer Gene Ther. 2013 Jan;20(1):17-24. doi: 10.1038/cgt.2012.75. Epub 2012 Nov 9.

PMID:
23138870
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.

Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song XT.

Mol Ther. 2014 Jan;22(1):102-11. doi: 10.1038/mt.2013.240. Epub 2013 Oct 17.

PMID:
24135899
[PubMed - indexed for MEDLINE]
11.

Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.

Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, Sadegh L, Sullivan JP, Shames DS, Brekken RA.

Mol Cancer Ther. 2009 Jul;8(7):1761-71. doi: 10.1158/1535-7163.MCT-09-0280. Epub 2009 Jun 30.

PMID:
19567820
[PubMed - indexed for MEDLINE]
Free Article
12.

Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.

Zhang W, Fulci G, Buhrman JS, Stemmer-Rachamimov AO, Chen JW, Wojtkiewicz GR, Weissleder R, Rabkin SD, Martuza RL.

Mol Ther. 2012 Jan;20(1):37-45. doi: 10.1038/mt.2011.187. Epub 2011 Sep 13.

PMID:
21915104
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Imaging of intratumoral inflammation during oncolytic virotherapy of tumors by 19F-magnetic resonance imaging (MRI).

Weibel S, Basse-Luesebrink TC, Hess M, Hofmann E, Seubert C, Langbein-Laugwitz J, Gentschev I, Sturm VJ, Ye Y, Kampf T, Jakob PM, Szalay AA.

PLoS One. 2013;8(2):e56317. doi: 10.1371/journal.pone.0056317. Epub 2013 Feb 18.

PMID:
23441176
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF.

Hou W, Chen H, Rojas J, Sampath P, Thorne SH.

Int J Cancer. 2014 Sep 1;135(5):1238-46. doi: 10.1002/ijc.28747. Epub 2014 Feb 18.

PMID:
24474587
[PubMed - indexed for MEDLINE]
15.

Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.

Zhang W, Fulci G, Wakimoto H, Cheema TA, Buhrman JS, Jeyaretna DS, Stemmer Rachamimov AO, Rabkin SD, Martuza RL.

Neoplasia. 2013 Jun;15(6):591-9.

PMID:
23730207
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy.

Frentzen A, Yu YA, Chen N, Zhang Q, Weibel S, Raab V, Szalay AA.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12915-20. doi: 10.1073/pnas.0900660106. Epub 2009 Jul 15.

PMID:
19617539
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma.

Gentschev I, Adelfinger M, Josupeit R, Rudolph S, Ehrig K, Donat U, Weibel S, Chen NG, Yu YA, Zhang Q, Heisig M, Thamm D, Stritzker J, Macneill A, Szalay AA.

PLoS One. 2012;7(5):e37239. doi: 10.1371/journal.pone.0037239. Epub 2012 May 15.

PMID:
22615950
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.

Piao Y, Liang J, Holmes L, Zurita AJ, Henry V, Heymach JV, de Groot JF.

Neuro Oncol. 2012 Nov;14(11):1379-92. doi: 10.1093/neuonc/nos158. Epub 2012 Sep 10.

PMID:
22965162
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer.

Weibel S, Hofmann E, Basse-Luesebrink TC, Donat U, Seubert C, Adelfinger M, Gnamlin P, Kober C, Frentzen A, Gentschev I, Jakob PM, Szalay AA.

J Transl Med. 2013 May 1;11:106. doi: 10.1186/1479-5876-11-106.

PMID:
23635329
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic.

Rintoul JL, Lemay CG, Tai LH, Stanford MM, Falls TJ, de Souza CT, Bridle BW, Daneshmand M, Ohashi PS, Wan Y, Lichty BD, Mercer AA, Auer RC, Atkins HL, Bell JC.

Mol Ther. 2012 Jun;20(6):1148-57. doi: 10.1038/mt.2011.301. Epub 2012 Jan 24.

PMID:
22273579
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk